세계의 면역글로불린 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Immunoglobulins Market is presumed to reach the market size of nearly USD 32.53 Billion by 2032 from USD 17.65 Billion in 2023 with a CAGR of 7.03% under the study period 2024 - 2032.

Immunoglobulins or antibodies are proteins the immune system produces to identify and neutralize foreign substances such as bacteria, viruses, and toxins. They play a crucial role in the body's defense against infections and diseases by binding to specific antigens and marking them for destruction by other immune cells. Immunoglobulins are categorized into different classes (IgM, IgG, IgA, IgD, and IgE), each with unique bodily functions and distribution. Deficiencies or abnormalities in immunoglobulin production can lead to immune disorders and increase susceptibility to infections, emphasizing the significance of maintaining a healthy immune system.

MARKET DYNAMICS

Several factors drive the market for immunoglobulins, including the increasing prevalence of immunodeficiency disorders, growing applications in therapeutic and diagnostic uses, and advancements in biotechnology and protein engineering. Immunoglobulins, also known as antibodies, play a crucial role in the immune system's defense against infections and diseases, driving demand for immunoglobulin-based therapies in treating immunodeficiency disorders, autoimmune diseases, and infectious diseases. Additionally, the growing adoption of immunoglobulin-based diagnostics for disease screening, monitoring, and research applications further fuels market growth. Moreover, advancements in biomanufacturing technologies, such as recombinant DNA technology and transgenic animal platforms, enable the production of therapeutic immunoglobulins with improved efficacy, safety, and scalability. Furthermore, regulatory approvals and market authorizations for novel immunoglobulin therapies and diagnostic assays drive market expansion as healthcare providers and patients seek innovative treatment options and diagnostic tools. However, limited access to healthcare services in developing regions, pricing pressures from generic immunoglobulin products, and regulatory challenges in product approval are likely to hinder market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of immunoglobulins. The growth and trends of immunoglobulins industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the immunoglobulins market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

• Neurology
• Immunology
• Hematology
• Others

By Route Of Administration

• Intravenous
• Subcutaneous
• Intramuscular

By End-User

• Hospitals
• Clinics
• Homecare

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Immunoglobulins market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Immunoglobulins market include Shire, CSL Behring, Kedrion Biopharma Inc., Grifols, S.A., Octapharma, China Biologic Products Holdings, Inc., Biotest AG, Sanquin, LFB SA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . IMMUNOGLOBULINS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Application
  • 3.7.2 Market Attractiveness Analysis By Route of Administration
  • 3.7.3 Market Attractiveness Analysis By End-user
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL IMMUNOGLOBULINS MARKET ANALYSIS BY APPLICATION

• 5.1 Overview by Application
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Application
• 5.4 Neurology Historic and Forecast Sales by Regions
• 5.5 Immunology Historic and Forecast Sales by Regions
• 5.6 Hematology Historic and Forecast Sales by Regions
• 5.7 Others Historic and Forecast Sales by Regions

6 . GLOBAL IMMUNOGLOBULINS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 6.1 Overview by Route of Administration
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Route of Administration
• 6.4 Intravenous Historic and Forecast Sales by Regions
• 6.5 Subcutaneous Historic and Forecast Sales by Regions
• 6.6 Intramuscular Historic and Forecast Sales by Regions

7 . GLOBAL IMMUNOGLOBULINS MARKET ANALYSIS BY END-USER

• 7.1 Overview by End-user
• 7.2 Historical and Forecast Data
• 7.3 Analysis by End-user
• 7.4 Hospitals Historic and Forecast Sales by Regions
• 7.5 Clinics Historic and Forecast Sales by Regions
• 7.6 Homecare Historic and Forecast Sales by Regions

8 . GLOBAL IMMUNOGLOBULINS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE IMMUNOGLOBULINS COMPANIES

• 9.1. Immunoglobulins Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF IMMUNOGLOBULINS INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Shire
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. CSL Behring
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Kedrion Biopharma Inc.
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Grifols S.A.
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Octapharma
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. China Biologic Products Holdings Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. Biotest AG
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Sanquin
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. LFB SA
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies